Marston, N. A., Gurmu, Y., Melloni, G. E. M., Bonaca, M., Gencer, B., Sever, P. S., . . . Sabatine, M. S. (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation (New York, N.Y.), 141(20), 1600. https://doi.org/10.1161/CIRCULATIONAHA.120.046397
Citácia podle Chicago (17th ed.)Marston, Nicholas A., et al. "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism." Circulation (New York, N.Y.) 141, no. 20 (2020): 1600. https://doi.org/10.1161/CIRCULATIONAHA.120.046397.
Citácia podľa MLA (8th ed.)Marston, Nicholas A., et al. "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism." Circulation (New York, N.Y.), vol. 141, no. 20, 2020, p. 1600, https://doi.org/10.1161/CIRCULATIONAHA.120.046397.